查詢結果分析
相關文獻
- Outcome of Graves' Disease after Antithyroid Drug Treatment in Taiwan
- Changes in Serum Thyroglobulin and Thyroid, Autoantibodies in Patients with Graves' Disease Treated with Antithyroid Drug and Their Relationship to Relapse
- 自體免疫性甲腺病
- 甲狀腺機能亢進症座談會
- 甲狀腺機能亢進的處理原則
- Uncommon Presentation of Combined Graves' Disease and Pulmonary Embolism in a 32-Year-Old Woman
頁籤選單縮合
題 名 | Outcome of Graves' Disease after Antithyroid Drug Treatment in Taiwan=臺灣抗甲腺藥物治療葛瑞夫茲病之結果 |
---|---|
作 者 | 王佩文; 劉瑞川; 董石城; 簡文彥; 盧永川; 陳振雄; 郭銘俊; 謝靜蓉; 王新台; | 書刊名 | 臺灣醫學會雜誌 |
卷 期 | 97:9 1998.09[民87.09] |
頁 次 | 頁619-625 |
分類號 | 415.931 |
關鍵詞 | 抗甲腺藥物; 葛瑞夫茲病; Graves' disease; Antithyroid treatment; |
語 文 | 英文(English) |
英文摘要 | The outcome of Graves' disease after treatment with antithyroid drugs (ATDs) varies widely among countries, and large-scale studies in Asia are rare. We investigated the associations of various clinical and laboratory features with the outcome of ATD therapy for Graves' disease in Taiwan. A total of 210 patients (177 women, 33 men; mean ± SD age, 41.7 ± 15.1 yr) treated with ATD in Taiwan were included. ATD therapy started with methimazole 30mg daily or propylthiouracil 300 mg daily and was continued until a euthyroid state was achieved. Afterwards, 154 patients received a maintenance dose of ATD alone, while 36 patients received a combination of an ATD and thyroxine (L-T□) - Patients were considered to be in remission if they remained in a euthyroid state for more than 2 years after drug withdrawal. The mean follow-up periods were 45.0 ± 20.9 months for patients with remission and 30.4 ± 19.8 months for those with relapse. Relapse occurred in 126 (60%) patients (luring the follow-up period, within 3 months after drug withdrawal in 47 (37%), and within 6 months in 60 (46%). The relapse rate was 100% among patients with two or more previous relapses. Patients with a second occurrence had a higher relapse rate than those with a first occurrence (84% vs 43%). Past history of recurrence, goiter size, thyroid-stimulating hormone level and thyrotropin-binding inhibition immunoglobulin activity at the end of ATD treatment were independently associated with relapse. Prolonged duration of treatment did not yield better results in patients with larger goiters or a history of recurrence, or both. Combination therapy with L-T□ yielded similar results to those achieved with ATD treatment alone. In conclusion, the relapse rate of Graves' disease after ATD treatment in Taiwanese patients was high, especially in those with a history of recurrence. The treatment duration and drug regimen did not affect the outcome. |
本系統中英文摘要資訊取自各篇刊載內容。